Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT00514475
First received: August 9, 2007
Last updated: May 3, 2012
Last verified: May 2008

August 9, 2007
May 3, 2012
November 2005
June 2009   (final data collection date for primary outcome measure)
Time to treatment failure (TTF) for PR/CRu patients receiving Zevalin-BEAM/BEAC [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Time to treatment failure (TTF) for PR/CRu patients receiving Zevalin-BEAM/BEAC
Complete list of historical versions of study NCT00514475 on ClinicalTrials.gov Archive Site
  • Safety [ Time Frame: Whole study ] [ Designated as safety issue: Yes ]
  • TTF for CR patients receiving BEAM/BEAC [ Time Frame: 3 year ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: 5 year ] [ Designated as safety issue: No ]
  • Time to progression [ Time Frame: 3 year ] [ Designated as safety issue: No ]
  • Response rates [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Value of PET [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Molecular response rates [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Molecular response and progression-free survival after Rituximab for molecular relapse [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Microarray gene expression analysis [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Safety
  • TTF for CR patients receiving BEAM/BEAC
  • Overall survival
  • Time to progression
  • Response rates
  • Value of PET
  • Molecular response rates
  • Molecular response and progression-free survival after Rituximab for molecular relapse
  • Microarray gene expression analysis
Not Provided
Not Provided
 
Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma
High-dose Therapy With Autologous Stem Cell Support in First Line Treatment of Mantle Cell Lymphoma- 90Y-Ibritumomab Tiuxetan in Combination With BEAM or BEAC to Improve Outcome for Patients Not in CR After Induction Treatment

The purpose of the study is to determine if outcome for patients with mantle cell lymphoma is improved by adding radioimmunotherapy to high-dose regimen before auto-transplant in patients who are not in CR after induction therapy.

Mantle cell lymphoma is considered to have the worst outcome of all non-Hodgkins lymphomas. Since 1997, the Nordic Lymphoma Group has conducted phase II studies in order to improve the results for this lymphoma subtype. The first study included high-dose therapy with autologous stem cell support in the first line of treatment. The results showed the importance of a high quality response to pre-transplant induction treatment, and that CHOP-based regimen alone did not achieve this. Thus, the second trial was designed to improve remissions by including Rituximab and high-dose Ara-C. Results now show that a high rate of molecular remission in the bone marrow was achieved, and the 3-year FFS was improved in comparison to the first study (80% vs 24%). Furthermore, patient who had a molecular relapse (t(11;14) or IgV-gene) were treated with 4 doses of Rituximab and many converted back to be PCR negative.

The present and thus third phase II study aims to improve the high-dose regimen by adding Zevalin radioimmunotherapy in patients who are not in CR prior to transplant. Data from the last trial show that patients not in CR at this point have a worse outcome (3 year FFS of 63%, vs 85% for CR patients). Monitoring for molecular relapse in the bone marrow will be done, and patients who become PCR positive will be treated with Rituximab in order to evaluate the value of this strategy.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Mantle Cell Lymphoma
Drug: 90Y-ibritumomab tiuxetan (Zevalin)
90Y-ibritumomab tiuxetan (Zevalin) at 0.4 mCi/kg is administered one week prior to start high-dose chemotherapy (BEAM/BEAC) in patients who have not achieved CR after induction therapy. Predosing with rituximab 250 mg/m2 one weeks prior to radioimmunotherapy and the same day.
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
160
June 2009
June 2009   (final data collection date for primary outcome measure)

Inclusion criteria:

  1. Age 18 - 65 years.
  2. Histologically confirmed (according to the WHO classification) mantle cell lymphoma stage II-IV at time point of diagnosis. The diagnosis has to be confirmed by phenotypic expression of CD5, CD20 and cyclin-D1 and most cases will have t(11;14) translocation.
  3. No previous treatment for lymphoma except radiotherapy or one cycle of any regimen and except patients treated in the previous phase II study who can be transferred to NLG-MCL-III before evaluation at week 15.
  4. WHO performance status of 0 - 3.
  5. Life expectancy of more than 3 months.
  6. Written informed consent.

Exclusion Criteria:

  1. Severe cardiac disease: cardiac function grade 3-4 (Appendix 1).
  2. Impaired liver, renal or other organ function not caused by lymphoma, which will interfere with the treatment.
  3. Pregnancy/lactation
  4. Men or woman of reproductive potential not agreeing to use acceptable method of birth control during treatment and for six moths after completion of treatment.
  5. Known HIV positivity
  6. Any other prior malignancy than non-melanoma skin cancer or stage 0 (in situ) cervical carcinoma.
  7. Known seropositivity for HCV, HbsAg or other active infection uncontrolled by treatment.
  8. Psychiatric illness or condition which could interfere with their ability to understand the requirements of the study.
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Norway
 
NCT00514475
2005-002003-17
Yes
Oslo University Hospital
Oslo University Hospital
Not Provided
Study Chair: Arne Kolstad, MD Nordic Lymphoma Group
Principal Investigator: Christian Geisler, MD Nordic Lymphoma Group
Principal Investigator: Erkki Elonen, MD Nordic Lymphoma Group
Principal Investigator: Anna Laurell, MD Nordic Lymphoma Group
Oslo University Hospital
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP